The Illumina-backed startup has launched with $44m and will develop therapeutics based on how the gut communicates with the brain and other organs.
US-based biotechnology startup Kallyope launched on Thursday with $44m of series A funding, supplied by investors including gene editing company Illumina.
Other investors in Kallyope include Lux Capital, Polaris Partners, The Column Group, Alexandria Venture Investments and Tony Evnin.
The company plans to combine sequencing, genetics, circuit mapping, neural imaging and bioinformatics technology to research how the gut communicates with the brain and other organs to affect a person’s physiological, metabolic and internal state.
The research will be used…
